CliffBio
small molecule

ZOSYN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Loss of exclusivity—loss of exclusivity
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOSYN
Active ingredientPIPERACILLIN SODIUM; TAZOBACTAM SODIUM
StrengthEQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalOctober 1993
Marketing statusDISCN

More from Wyeth

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.